Observational Study Evaluating Efficacy, Tolerability and Treatment Algorithm of Advanced Renal Cell Cancer Patients Under Afinitor Treatment
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Metastatic Renal Cell Carcinoma (mRCC)
Both
Metastatic Renal Cell Carcinoma (mRCC)
Trial Information
Observational Study Evaluating Efficacy, Tolerability and Treatment Algorithm of Advanced Renal Cell Cancer Patients Under Afinitor Treatment
Inclusion Criteria:
- Age > 18 years
- Confirmed diagnosis of advanced renal cell cancer
- Progression on or after one VEGF -TKI (e.g. sunitibin, sorafenib)
- Written informed consent
Exclusion Criteria:
None
Other protocol-defined inclusion/exclusion criteria may apply
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Time to progression (TTP)
Outcome Time Frame:
maximum of 12 months after inclusion of the last patient
Safety Issue:
No
Principal Investigator
Novartis Pharmaceuticals
Investigator Role:
Study Director
Investigator Affiliation:
Novartis Pharmaceuticals
Authority:
Norway: Regional Etisk Komite Nord
Study ID:
CRAD001LNO03
NCT ID:
NCT01390519
Start Date:
May 2011
Completion Date:
December 2013
Related Keywords:
- Metastatic Renal Cell Carcinoma (mRCC)
- mRCC,
- observational,
- Afinitor,
- everolimus,
- 2.line
- Carcinoma
- Carcinoma, Renal Cell
Name | Location |
|---|
